First Trust Nasdaq Pharmaceuticals ETF

1. 01

   Set a 52-week high on 4 Nov 2026

   Closed at $44.86 on 4 Nov 2026: 0.1% below the 52-week high of $44.91 (4 Nov 2026) and 50.1% above the low of $29.89 (7 Nov 2025).

   Daily price bars, split-adjusted · as of 4 Nov 2026

2. 02

   Ahead of SPY over 1 year

   1 month: +10.9% (SPY −1.6%). 3 months: +13.9% (SPY −0.4%). 1 year: +50.3% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: FTXH, SPY · as of 4 Nov 2026

3. 03

   Above its 50- and 200-day averages

   The 4 Nov 2026 close of $44.86 was 7.4% above its 50-day average ($41.79) and 20.1% above its 200-day average ($37.36). It has closed above the 200-day for 310 sessions, since 13 Aug 2025. The 50-day average crossed above the 200-day on 4 Sep 2025, 294 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

4. 04

   RSI(14) at 71.8, 70 or above

   The 14-session relative strength index closed at 71.8 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.

   Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

5. 05

   Short interest at 0.3% of shares outstanding

   69.1K shares were sold short at the 15 Oct 2026 settlement, 0.3% of the 26.6M shares outstanding; covering them would take 1.0 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

At the 4 Nov 2026 close